Stockscreener 앱 받기
4.84
9.53%
-0.51
시간 외 거래:
4.88
0.04
+0.83%
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
BioAge Labs Initiates Dosing in Phase 2 QUELL-DME Trial for Diabetic Macular Edema - Kalkine Media
BioAge Labs (Nasdaq:BIOA)Stock Analysis - Simply Wall Street
BioAge Labs (NasdaqGS:BIOA) Stock Forecast & Analyst Predictions - Simply Wall Street
BioAge Labs at Cantor conference: shifts focus to retina By Investing.com - Investing.com Canada
Transcript : BioAge Labs, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 11 - marketscreener.com
BIOA: Phase II trials for BGE-102 target DME and metabolic diseases, with pivotal data expected next year - TradingView
A daily pill for diabetic eye disease enters a Phase 2 trial - Stock Titan
BioAge Labs remains a buy despite 40% drop, bac... - Pluang
BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off (BIOA) - Seeking Alpha
BioAge Labs to Present at Upcoming Investor Conferences - markets.businessinsider.com
BioAge Labs to Present at Upcoming Investor Conferences - Yahoo Finance
Bioage Labs Market Sentiment - Benzinga España
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know - qz.com
354,395 Shares in BioAge Labs, Inc. $BIOA Bought by Walleye Capital LLC - MarketBeat
BioAge Labs, Inc.: Shareholders Board Members Managers and Company Profile | US09077V1008 - marketscreener.com
Cormorant Asset Management (BIOA) discloses 5.38% BioAge Labs ownership stake - Stock Titan
214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP - MarketBeat
BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Renaissance Technologies LLC Buys 120,188 Shares of BioAge Labs, Inc. $BIOA - MarketBeat
BIOA Q2 2026 Earnings: Narrower-than-Expected Loss Offers Modest ReliefEarnings Stability Report - vinanet.vn
We're Not Very Worried About BioAge Labs' (NASDAQ:BIOA) Cash Burn Rate - Moomoo
BioAge Labs (BIOA) Retreats 2.3% Toward Key Support as Momentum FadesRSI Overbought Alerts - vinanet.vn
Morgan Stanley Maintains BioAge Labs(BIOA.US) With Hold Rating, Cuts Target Price to $20 - Moomoo
Roth MKM Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Analysts’ Opinions Are Mixed on These NA Stocks: BioAge Labs, Inc. (BIOA) and Fiserv (FISV) - The Globe and Mail
BIOAGE Labs Inc (BIOA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BIOAGE Labs Inc (BIOA) Stock News Today - TradingKey
A Quick Look at Today's Ratings for BioAge Labs(BIOA.US), With a Forecast Between $21 to $73 - Moomoo
BioAge Labs, Inc. Stock 12‑Month Price Target Cut to $35.62, Implies 224% Upside - TradingView
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
BioAge Labs (NASDAQ:BIOA) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
BioAge Labs, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
BIOA: BGE-102 clinical trials advanced, net loss increased, and cash reserves remain strong - TradingView
BioAge Labs reports Q2 2026 net loss $26.1M, cash and securities $381.3M; BGE-102 Phase 2 dosing underway - TradingView
BioAge Labs, Inc. Q2 2026: Revenue $2.45M, EPS $(0.58) — 10-Q Summary - TradingView
BioAge Labs (NASDAQ: BIOA) builds $381.3M cash buffer as BGE-102 advances - Stock Titan
BioAge Labs | 10-Q: Q2 2026 Earnings Report - Moomoo
BioAge Labs Reports Q2 2026 Results, Doses First Patient in QUELL-CV and Advances BGE-102 Clinical Development - Quiver Quantitative
BioAge Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BioAge's BGE-102 Enters Obesity Trial; Eye Study Planned - Stock Titan
Price to earnings forward of BioAge Labs, Inc. – SWB:Y7G - TradingView
BIOA Q2'26 Earnings: revenue estimate is 1.50M USD - TradingView
Piper Sandler Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $73 - Moomoo
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates - markets.businessinsider.com
BioAge Labs posts partial recovery after deep selloff, rises 19% (BIOA:NASDAQ) - Seeking Alpha
Roth MKM Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Weekly Recap: ZEUS miss lifts BGE-102 and Analysts cut BIOA PTs, keep Buy - TradingView
Janus Henderson Group PLC Acquires 1,685,063 Shares of BioAge Labs, Inc. $BIOA - MarketBeat
0.63%
자본화:
|
볼륨(24시간):